Results 11 to 20 of about 423,816 (314)

Pulmonary pleomorphic carcinoma presenting as undifferentiated non-small cell carcinoma with giant cells: A case report and review of literature

open access: yesRespiratory Medicine Case Reports, 2020
Pulmonary pleomorphic carcinoma (PPC) is a poorly differentiated non-small cell lung carcinoma, including squamous cell carcinoma, adenocarcinoma, or undifferentiated non-small cell lung carcinoma with at least 10% spindle and/or giant cells.
Jae-Han Jeong   +3 more
doaj   +1 more source

Leser‐Trélat syndrome secondary to non‐small‐cell lung carcinoma

open access: yesClinical Case Reports, 2022
The syndrome of Leser‐Trélat (LT) is a rare paraneoplastic syndrome. However, patients presenting with the sign of Leser‐Trélat should be considered to harbor an occult malignancy or a progressive tumor disease until “proven” otherwise.
Rim Khemakhem   +4 more
doaj   +1 more source

pTNM System in Non Small Cell Lung Carcinoma

open access: yesIndonesian Journal of Cancer, 2008
Prognosis karsinoma paru berhubungan dengan berbagai macam faktor, antara lain : usia, jenis kelamin, ukuran tumor, staging, jenis sel dan derajat diferensiasi, invasi kepembuluh darah, dinding dada, efusi pleura, adanya jaringan ikat, keterlibatan KGB ...
Heriawaty Hidajat   +5 more
doaj   +1 more source

Predictive testing in non-small cell lung carcinoma

open access: yesKlinicka onkologie, 2021
Predictive testing is a crucial part of the complete diagnostic process of non-small cell lung cancer (NSCLC) and a necessary requirement in order to determine proper course of treatment. However, the possibilities of testing and the spectrum of examined markers are quickly evolving as a result of the progress in diagnostic and therapeutic ...
P, Dundr   +4 more
openaire   +2 more sources

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. [PDF]

open access: yesPLoS ONE, 2011
Squamous cell lung carcinomas account for approximately 25% of new lung carcinoma cases and 40,000 deaths per year in the United States. Although there are multiple genomically targeted therapies for lung adenocarcinoma, none has yet been reported in ...
Amit Dutt   +11 more
doaj   +1 more source

Influence of ABO blood group on susceptibility to different pathological types of lung cancer: a retrospective study

open access: yesWorld Journal of Surgical Oncology, 2022
Purpose Current research has shown a link between ABO blood group and many diseases. The purpose of this study aimed to investigate the influence of the ABO blood group on the risk of developing different pathological types of lung cancer.
Haotian Yang   +8 more
doaj   +1 more source

Long noncoding nature brain-derived neurotrophic factor antisense is associated with poor prognosis and functional regulation in non–small cell lung caner

open access: yesTumor Biology, 2017
In this study, we evaluated the prognostic potential and functional regulation of human nature antisense, brain-derived neurotrophic factor antisense, in non–small cell lung cancer.
MingJing Shen   +5 more
doaj   +1 more source

Durable response to durvalumab‐based immunochemotherapy in small‐cell lung carcinoma transformation from EGFR‐mutant non–small cell lung cancer: A case report

open access: yesThoracic Cancer, 2022
Combined small‐cell lung carcinoma (C‐SCLC) is small‐cell lung carcinoma (SCLC) with added non–small‐cell morphology. We report a case of epidermal growth factor receptor (EGFR) mutation‐positive C‐SCLC in an 84‐year‐old patient with metastatic brain ...
Yu‐Chung Li
doaj   +1 more source

Epigenetics in non-small cell lung carcinomas

open access: yesSalud Pública de México, 2019
Objective. To perform a systematic review of the main epi­genetic aberrations involved in non-small cell lung carcinomas’ (NSCLC) diagnosis, progression, and therapeutics. Materials and methods. We performed a systematic review of the scientific literature on lung cancer epigenetics, focusing on NSCLC. Results.
Irlanda Peralta-Arrieta   +3 more
openaire   +3 more sources

KAN0438757: a novel PFKFB3 inhibitor that induces programmed cell death and suppresses cell migration in non-small cell lung carcinoma cells . [PDF]

open access: yesBiotechnologia Acta, 2023
Aim. PFKFB3 is glycolytic activators that is overexpressed in human lung cancer and plays a crucial role in multiple cellular functions including programmed cell death.
Deniz Özdemir   +2 more
doaj  

Home - About - Disclaimer - Privacy